Severe Acute Respiratory Infection - Preparedness (COVID-19 and Influenza)

• Conditions: Pneumonia, Viral

• Registration Number: NCT04786301
• Lead Sponsor: University of Washington

Brief Summary

Severe Acute Respiratory Infection (SARI) is defined by the World Health Organization (WHO) as acute respiratory infection with a history of fever ≥38°C and cough for less than 10 days duration that requires hospital admission. SARI-PREP is a multi-center consortium funded by the CDC Foundation being assembled with the goal of providing the infrastructure to rapidly collect prospective data on clinical risks and outcomes, hospital-level stress, and biologic specimens that will aid in the rapid development of diagnostic and treatment approaches. A current example of a form of SARI to be targeted by SARI-PREP is COVID-19 the acute respiratory infectious disease caused by SARS-CoV-2 infection. COVID-19 has a broad set of manifestations and severity with a subset of affected patients developing severe disease leading to respiratory failure and other forms of organ dysfunction. As with many outbreaks of novel viral pathogens causing SARI there was no efficacious therapeutic intervention at the beginning of the COVID-19 pandemic. Furthermore, while there is emerging knowledge of clinical risks for severe COVID-19, there remains a paucity of information about the viral dynamics and host responses that might indicate a patient is at high risk for poor outcomes.

The COVID-19 pandemic will be the initial target of the SARI-PREP consortium with the overall goal of developing a multi-institutional collaborative network of Acute Care Hospitals that will rapidly enroll, sample, and follow patients admitted with severe COVID-19 and to develop research protocols to rapidly determine demographic, clinical, host molecular, virologic, and institutional correlates of outcome. Overall, the information gained from this effort will help to rapidly inform and improve clinical management of epidemic/pandemic SARI patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-30
• Status Verified: 2021-03
• Study First Submitted: 2021-03-03
• Study First Submitted QC: 2021-03-03
• Study First Posted: 2021-03-08
• Last Update Submitted: 2021-03-09
• Last Update Posted: 2021-03-12
• Primary Completion: 2022-01
• Study Completion: 2022-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 1200

Inclusion Criteria

• Admission to an acute care or intensive care unit with a clinical syndrome of lower respiratory tract infection suspicious for viral SARI:
• fever
• cough
• AND (radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) OR SpO2 ≤ 94% on room air OR requiring new supplemental oxygen (above baseline if preexisting) OR requiring invasive or non-invasive mechanical ventilation).
• confirmed viral cause for SARI by respiratory viral RT-PCR testing.

Read More

Exclusion Criteria

• Prisoners or wards of the state
• Inability to consent or lack of availability of legal surrogate
• Do not attempt resuscitation/do not intubate status on admission

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ventilator-free days (VFD)	30 days	Number of days alive and free of mechanical ventilation

Secondary Outcome Measures

Name	Time	Method
World Health Organization respiratory failure ordinal score	30 days
Mortality	28-day and 90-day
Organ failure free days	30 days

Trial Locations

Locations (2)

Bellevue Hospital Center; 🇺🇸 New York, New York, United States

NYU Langone Medical Center; 🇺🇸 New York, New York, United States